With 0.26 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.43 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $102.8 whereas the lowest price it dropped to was $99.49. The 52-week range on IRTC shows that it touched its highest point at $128.52 and its lowest point at $55.92 during that stretch. It currently has a 1-year price target of $130.92. Beta for the stock currently stands at 1.33.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IRTC was up-trending over the past week, with a rise of 2.20%, but this was down by -2.09% over a month. Three-month performance dropped to -5.64% while six-month performance rose 67.90%. The stock lost -8.09% in the past year, while it has gained 11.97% so far this year. A look at the trailing 12-month EPS for IRTC yields -3.64 with Next year EPS estimates of -0.62. For the next quarter, that number is -0.98. This implies an EPS growth rate of 53.86% for this year and 63.04% for next year.
Float and Shares Shorts:
At present, 31.39 million IRTC shares are outstanding with a float of 30.61 million shares on hand for trading. On 2025-03-31, short shares totaled 2.93 million, which was 934.0 higher than short shares on 1740700800. In addition to Mr. Quentin S. Blackford as the firm’s President, CEO & Director, Mr. Patrick Michael Murphy J.D. serves as its Chief Business & Legal Officer.
Institutional Ownership:
Through their ownership of 1.13494 of IRTC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, IRTC reported revenue of $164325000.0 and operating income of -$4083000.0. The EBITDA in the recently reported quarter was $8742000.0 and diluted EPS was -$0.04.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IRTC since 17 analysts follow the stock currently. There are 14 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IRTC analysts setting a high price target of 152.0 and a low target of 104.0, the average target price over the next 12 months is 130.91667. Based on these targets, IRTC could surge 50.55% to reach the target high and rise by 3.01% to reach the target low. Reaching the average price target will result in a growth of 29.67% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.44972 being high and -$3.87683 being low. For IRTC, this leads to a yearly average estimate of -$3.66875. Based on analyst estimates, the high estimate for the next quarter is -$0.2 and the low estimate is -$0.8. The average estimate for the next quarter is thus -$0.43.
